CEO Moshe Mizrahy’s Group Offers to Take InMode Private at $16.20 Per Share
Board forms special committee to evaluate the offer.
Board forms special committee to evaluate the offer.
Eli Lilly participates in Absci’s $100M equity offering to fund ABS-201, a novel prolactin receptor antibody showing strong safety in Phase 1 for pattern hair loss and endometriosis.
The deals cover key gene therapy platforms and the Fabry disease program in a court-supervised auction.
The combined company will list on Nasdaq under the ticker TUDE in H2 2026.
Boundless Bio and Serapha Bio announce a merger and $230 million private placement. The combined company will advance SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency (AATD).
MacroGenics receives $24.5 million from Sanofi after FDA expands TZIELD approval to children aged 8-17 with newly diagnosed stage 3 Type 1 diabetes.